Abstract:Background: The enteric-coated mycophenolate sodium (EC-MPS), whose active constituent is mycophenolic acid (MPA), has been widely clinically used for organ transplant recipients. However, its absorption is delayed due to its special designed dosage form, which results in difficulty to monitor the exposure of the MPA in patients receiving the EC-MPS. This study was aimed at developing a relatively practical and precise model with limited sampling strategy to estimate the 12-hour area under the concentration–time curve (AUC0–12 h) of MPA for Chinese renal transplant recipients receiving EC-MPS. Methods: A total of 36 Chinese renal transplant recipients receiving the EC-MPS and tacrolimus were recruited in this study. The time point was 2 weeks after the transplantation for all the patients. The MPA concentrations were measured with enzyme-multiplied immunoassay technique for 11 blood specimens collected predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours after the morning dose of EC-MPS. The measured AUC was calculated with these 11 points of MPA concentrations with the linear trapezoidal rule. Limited sampling strategy was used to develop models for estimated AUC in the model group (n = 18). The bias and precision of different models were evaluated in the validation group (n = 18). Results: C4 showed the strongest correlation with the measured AUC. The best 3 time point equation was 6.629 + 8.029 × C0 + 0.592 × C3 + 1.786 × C4 (R 2 = 0.910; P < 0.001), whereas the best 4 time point equation was 3.132 + 5.337 × C0 + 0.735 × C3 + 1.783 × C4 + 3.065 × C8 (R 2 = 0.959; P < 0.001). When evaluated in the validation group, the 4 time point model had a much better performance than the 3 time point model: for the 4 time point model: R 2 = 0.873, bias = 0.505 [95% confidence interval (CI), −10.159 to 11.170], precision = 13.370 (95% CI, 5.186–21.555), and 77.8% of estimated AUCs was within 85%–115% of the measured AUCs; for the 3 time point model: R 2 = 0.573, bias = 6.196 (95% CI, −10.627 to 23.018), precision = 21.286 (95% CI, 8.079–34.492), and 50.0% of estimated AUCs was within 85%–115% of the measured AUCs. Conclusions: It demanded at least 4 time points to develop a relatively reliable model to estimate the exposure of MPA in renal transplant recipients receiving the EC-MPS. The long time span needed restricted its application, especially for the outpatients, but it could be a useful tool to guide the personalized prescription for the inpatients.

Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid

Population Pharmacokinetic Modelling for Enterohepatic Circulation of Mycophenolic Acid in Healthy Chinese and the Influence of Polymorphisms in Ugt1a9

Pharmacokinetics Study of Mycophenolate Mofetil in Renal Transplantation Patients

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Enterohepatic circulation of mycophenolic acid in rat models

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Pharmacokinetics Of Mycophenolic Acid In Chinese Patients With Liver Transplant (In Chinese) (Vol 41, Pg 1157, 2006)

Pharmacokinetics of Mycophenolic Acid and Determination of Area under the Curve by Abbreviated Sampling Strategy in Chinese Liver Transplant Recipients

Validation of Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure in Chinese Adult Liver Transplant Recipients.

Evaluation of Mycophenolic Acid Exposure by Limited Sampling Strategy in Chinese Adult Renal Transplant Recipients Receiving Mycophenolate Mofeil and Tacrolimus

Investigation on Pharmacokinetics of Mycophenolic Acid in Chinese Adult Renal Transplant Patients.

Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients

Evaluation of the Area under the Curve of Enteric-Coated Mycophenolate Sodium Using a Limited Sampling Strategy in Chinese Kidney Transplant Recipients .

Pharmacokinetics of Free Mycophenolic Acid and Limited Sampling Strategy for the Estimation of Area under the Curve in Liver Transplant Patients.

Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation.

Evaluation of Mycophenolic Acid Exposure Using a Limited Sampling Strategy in Renal Transplant Recipients

Pharmacokinetics of Mycophenolic Acid and its Metabolites in Chinese Liver Transplant Patients after Ad-ministration of Enteric-coated Mycophenolate Sodium(EC-MPS)Tablets

Estimation of Mycophenolic Acid Area under the Curve with Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium

Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant

Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages

Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients after Administration of EC-MPS.